
|Videos|January 7, 2014
Biosimilar Interchangeability
Interchangeability designations for biosimilars would make therapy substitutions easier for pharmacists, noted Steven Lucio of Novation, but the FDA has said they will not grant an interchangeability status to a biosimilar upon initial approval.
Advertisement
Interchangeability designations for biosimilars would make therapy substitutions easier for pharmacists, noted Steven Lucio of Novation, but the FDA has said they will not grant an interchangeability status to a biosimilar upon initial approval.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Paradigm Shift in Lipid Management: Highlights from the NLA 2026 Scientific Sessions Opening Session
2
ATTR-CM Red Flags, Treatment Evidence, and the Pharmacist's Role in Care
3
FDA Approves Belzutifan Plus Pembrolizumab for Adjuvant Treatment of High-Risk Clear Cell RCC
4
Staging the Heart: NLA and EAS Reveal a New Era of Precision Lipidology and Imaging
5


































































































































